Lviv clinical bulletin 2013, 2(2): 37-45

https://doi.org/10.25040/lkv2013.02.037

Treatment of the Liver Cirrhosis: Modern Principles, Considering Syntropic Co- and Multimorbid Lesions of other Organs and Systems of Organs

Posted onAuthorAdminЗалишити коментар / Leave a comment

M. Abrahamovych, M. Farmaha

Danylo Halytsky Lviv National Medical University

Introduction. Cirrhosis of the liver is a frequent chronic polyethyologic disease of the internal organs with polymorphous syntropic lesions, which often causes early disability and death of patients – that is why it is necessary to improve the principles of complex differentiated treatment taking into account extrahepatic manifestations of the disease.

Aim. To improve the algorithm and to improve the efficiency of treatment of patients with cirrhosis of the liver by taking into account detected extrahepatic co- and polymorbid syntropic lesions of other organs and systems.

Materials and methods. The study included 1713 patients with cirrhosis (75.7% of men, 24.3% of women, age 18-86), who performed a comprehensive examination of all organs and systems in accordance with the requirements of modern medicine. Subsequently, patients were divided according to the criteria for classification of C. G. Child – R. N. Pugh by severity at A (38.1%), B (52.3%) and C (9.6%) classes, and a comprehensive differential treatment was performed for 4-6 weeks. The control group consisted of 302 patients, representative of gender, age and severity of liver cirrhosis, which were treated according to the generally accepted method.

Results. Among patients with cirrhosis of the liver, 74.3% had varicose veins of the esophagus, 61.3% had gastropathy, 48.2% had varicose hemorrhoidal veins, 19.2% had arterial hypertension, 56.4% arterial hypotension, 57,3% – secondary cardiomyopathy, 27.5% – rhythm disorders, 65,3% – disorders of conduction, 82,9% – signs of hepatopulmonary syndrome, 8,9% – portopulmonal hypertension, 0.8% – signs of hepatolateral syndrome type І, and 3.3% – type II, 56.0% – secondary encephalopathy, 73.1% – signs of the disorders of the autonomic nervous system, 60.5% – osteopenia and 39.5% – osteoporosis, 42.3% – anemia, 29.8% – coagulopathy and 94.2% – signs of skin lesions.

In 64.2% of the patients treated using the system we had modified, good results were obtained, in 28.7% the results were satisfactory and 7.1% – were not satisfactory. 73.1% had a good result in patients with class A of liver cirrhosis, 63.9% – class B and 61.8% – class C. The number of patients with satisfactory results was roughly the same in all groups (26.5% -30.4%). In group A, there were no patients with poor treatment outcomes, in group B – 5.7%, and in group C they were 11.7%. The presented actual material allows us to assert that the complex treatment we have modified is effective in 92.9% of the patients with liver cirrhosis. In the significantly lower number of patients treated using the usual method compared to the experimental group (47.4%), good results were obtained, and this was due to a significant increase in the number of patients with only a satisfactory result of treatment (46.7%). In 5.6% of the patients, the results of treatment were not satisfactory, and 0.3% the results were poor. 51.3% of the patients with a good result were patients of class A of liver cirrhosis, 49.4% – class B and 20.7% – class C. The number of patients with satisfactory results, as in the experimental group, was approximately identical in quantity in groups A, B and C (from 46.2% to 48.3%). In group A, 1.7% of the patients had a poor outcome, in group B they were 4.4%, and in group C – 27.6%. Consequently, the generally accepted comprehensive treatment is effective in 94.1% of patients with liver cirrhosis, but for qualitative indices, it is significantly lower than the medical complex we have modified.

Conclusions. Modified by the authors, the complex differential treatment of patients with liver cirrhosis, taking into account the presence of polymorbid syntropic lesions, as well as the traditional one gives a positive result, but the effectiveness of conventional treatment is lower compared to the complex we modified.

Reference

  1. Alekberova ZS, Barskov VH. Colchicine in Rheumatology – Yesterday and Today. Will It Be Tomorrow? Modern Rheumatology. 2010; 2: 14-20. (Russian)
  2. Angeli P, Moranda F. Optimal Management of Hepatorenal Syndrome in Patients with Cirrhosis. Health of Ukraine. 2010;17:55-56. (Russian)
  3. Harbuzenko DV. Multiorgan Hemodynamic Disorders in Liver Cirrhosis. Therapeutic Archive. 2007;79(2):73-77. (Russian)
  4. Kharchenko NV, Babak OYa, editors. Gastroenterology. Kyiv, 2007. 720 p. (Ukrainian)
  5. Gundermann K-J. The Latest Data on the Mechanisms of Action and Clinical Efficacy of Essential Phospholipids. Clinical Perspectives of Gastroenterology, Hepatology. 2002;2:21-28. (Russian)
  6. Zhuravleva LV. The State of the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension, Chronic Hepatitis and with Their Combination. Medicine Today and Tomorrow. 2005;2:35-39. (Russian)
  7. Kolesnikova EV. Ursodeoxycholic Acid – “Ursolisin”: Application in the Present and Future. Ukrainian Therapeutic Journal. 2008;4:96-101. (Russian)
  8. Complex Antihomotoxic Drugs: manual for doctors (electronic version). Heel, 2008. (Russian)
  9. Perederiy VH, Tkach SM. The Maastricht Consensus IV-2010: the Main Provisions and Their Relevance for Ukraine. Modern Gastroenterology. 2011;6:133-136. (Russian)
  10. Prihod’ko VYu, Micropulo IR, Kononenko EA. Hepatoprotectors in Therapeutic Practice. Medications of Ukraine. 2011;9:84-89. (Russian)
  11. Tkach SM. Efficacy and Safety of Hepatoprotectors in Terms of Evidence-Based Medicine. Health of Ukraine. 2009;6:7-10. (Russian)
  12. Longacre AV, Imaeda A, Garcia-Tsao G, Fraenkel L. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. Hepatology. 2008;47(1):169-176. https://doi.org/10.1002/hep.21945
  13. Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004;127(2):476-484. https://doi.org/10.1053/j.gastro.2004.05.004
  14. Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005;3(2):184-191. https://doi.org/10.1016/S1542-3565(04)00667-6
  15. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-1368. https://doi.org/10.1053/j.gastro.2008.02.014
  16. Abrams GA, Fallon MB. Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. J Clin Gastroenterol. 1998;27(3):232-235.
  17. Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C et al. Acute hemodynamic response to β-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology. 2009;137(1):119-128. https://doi.org/10.1053/j.gastro.2009.03.048
  18. Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency adjusted Q–T interval (QTc) in patients with cirrhosis. J Hepatol. 2004;40(2):239-246. https://doi.org/10.1016/j.jhep.2003.10.026
  19. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42(4):762-771. https://doi.org/10.1002/hep.20866
  20. Gua-abens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98(10):2268-2274. https://doi.org/10.1016/S0002-9270(03)00550-1
  21. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. Br Med J. 2004;328(7447):1046. https://doi.org/10.1136/bmj.38048.506134.EE
  22. Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. Ann Hepatol. 2011;10(1 Suppl):15-20.
  23. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689-1697. https://doi.org/10.1111/j.1572-0241.2008.01828.x
  24. Arroyo V, Terra C, Gines P. New treatment of hepatorenal syndrome. Semin Liver Dis. 2006;26(3):254-264. https://doi.org/10.1055/s-2006-947293
  25. Avidan B. The use of albumin in patients with decompensated cirrhosis: is not Justified. Isr Med Assoc J. 2005;7(2):118-120.
  26. Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med. 2008;36(4 Suppl):179-186.
  27. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18(2):152-156. https://doi.org/10.1046/j.1440-1746.2003.02934.x
  28. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol. 1998;29(4):565-570. https://doi.org/10.1016/S0168-8278(98)80151-7
  29. Berk DP, Chalmers Т. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med. 1970;73(3):393-396. https://doi.org/10.7326/0003-4819-73-3-393
  30. Biecker Е. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol. 2011;17(10):1237-1248. https://doi.org/10.3748/wjg.v17.i10.1237
  31. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest. 2006;36(3 Suppl):67-70.
  32. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatology. 2005;42(1):68-74. https://doi.org/10.1016/j.jhep.2004.09.008
  33. Pozzi M, Grassi G, Ratti L, Favini G, Dell’Oro R, Redaelli E et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol. 2005;100(5):1110-1116. https://doi.org/10.1111/j.1572-0241.2005.41060.x
  34. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardio toxicity of the cancer therapeutic agent imatinib mesilate. Nat Med. 2006;12(8):908-916. https://doi.org/10.1038/nm1446
  35. Child CG, Turcotte JG. Surgery and portal hypertension. The liver and portal hypertension. Child CG, editor. Philadelphia: Saunders, 1964. p. 50-
  36. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. Heart Lung Transplant. 2005;24(4):498-500. https://doi.org/10.1016/j.healun.2004.01.017
  37. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V et al. Circulatory function and hepatorenal syndrome. Hepatology. 2005;42(2):439-447. https://doi.org/10.1002/hep.20766
  38. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48(1):196-203. https://doi.org/10.1002/hep.22275
  39. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46(4):1271-1278. https://doi.org/10.1002/hep.21852
  40. Halank M, Kolditz M, Miehlke S, Schiemanck S, Schmeisser A, Hoeffken G. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral Wien Med Wochenschr. 2005;155(15-16):376-380.
  41. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46(3):399-407. https://doi.org/10.3349/ymj.2005.46.3.399
  42. Mills PR, Rae AP, Farah DA, Russell RI, Lorimer AR, Carter DC. Comparison of three adrenoceptor blocking agents in patients with cirrhosis and portal hypertension. Gut. 1984;25(1):73-78. https://doi.org/10.1136/gut.25.1.73
  43. Albillos A, Lledó JL, Rossi I, Pérez-Páramo M, Tabuenca MJ, Ba-ares R et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. 1995;109(4):1257-1265.
  44. D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidencebased approach. Semin Liver Dis. 1999;19(4):475-505. https://doi.org/10.1055/s-2007-1007133
  45. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409. https://doi.org/10.1056/NEJM199908053410603
  46. Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology. 2002;36(2):374-380. https://doi.org/10.1053/jhep.2002.34343
  47. Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, García-Ramos G, Fernández-Zertuche M et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006;5(4):281-288.
  48. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology. 2000;32(4):859-865. https://doi.org/10.1053/jhep.2000.7519
  49. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: varices and variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology. 2001;120(3):726-748. https://doi.org/10.1053/gast.2001.22580
  50. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Eng J Med. 2010;362(9):823-832. https://doi.org/10.1056/NEJMra0901512
  51. Gerbes AL, Gulberg V. Progress in treatment of massive ascites and hepatorenal Syndrome. World J Gastroenterol. 2006;12(4):516-519. https://doi.org/10.3748/wjg.v12.i4.516
  52. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the study of liver diseases practice guidelines. Hepatology. 2000;31(4):1005-1013.
  53. Mikulic E, Mu-oz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther. 1983;34(1):56-59. https://doi.org/10.1038/clpt.1983.129
  54. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84(5):313-322. https://doi.org/10.1097/01.md.0000180792.80212.5e
  55. De BK, Sen S, Biswas PK, Sanyal R, Majumdar D, Biswas J. Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology. 2000;118(1):192-196. https://doi.org/10.1016/S0016-5085(00)70428-8
  56. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation. 1974;49(4):754-760. https://doi.org/10.1161/01.CIR.49.4.755
  57. Krug S, Seyfarth HJ, Hagendorff A, Wirtz H. Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur J Gastroenterol Hepatol. 2007;19(12):1140-1143. https://doi.org/10.1097/MEG.0b013e328220ed72
  58. Kuntzen C, Guelberg V, Gerbes AL. Use of a mixed receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology. 2005;128(1):164-168. https://doi.org/10.1053/j.gastro.2004.09.005
  59. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125(3):941-966. https://doi.org/10.1016/S0016-5085(03)01062-X
  60. Lin SM, Lee CS, Kao PF. Low-dose dopamine infusion in cirrhosis with refractory ascites. Int J Clin Pract. 1998;52(8):533-536.
  61. Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol. 2002;26(10):842-847.
  62. Elner VM, Mintz R, Demirci H, Hassan AS. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Trans Am Ophthalmol Soc. 2005;103:69-73.
  63. Lock BG, Pandit K. Evidence-based emergency medicine/systematic review abstract. Is flumazenil an effective treatment for hepatic encephalopathy? Ann Emerg Med. 2006;47(3):286-288. https://doi.org/10.1016/j.annemergmed.2006.01.021
  64. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome – experience in 300 patients. Transplantation. 1991;51(2):428-430. https://doi.org/10.1097/00007890-199102000-00030
  65. Ma Z. Management of cirrhotic cardiomyopathy. Medical Management of Liver Disease. Krawitt EL, editor. New-York: Marcel Dekker, 1999. p. 583-589.
  66. Magan AA, Khalil A, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol. 2010;16(41):5139-5147. https://doi.org/10.3748/wjg.v16.i41.5139
  67. Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion. 2006;73(1 Suppl):94-101.
  68. Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion. 2006;73(1 Suppl):86-93.
  69. von Mehren M. Targeted therapy with imatinib: hits and misses? J Clin Oncol. 2005;23:8-10.
  70. Miñano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am. 2010;39(3):681-695. https://doi.org/10.1016/j.gtc.2010.08.015
  71. Levey JM, Bjornsson B, Banner B, Kuhns M, Malhotra R, Whitman N et al. Mixed cryoglobulinemia in chronic hepatitis C infection. A clinicopathologic analysis of 10 cases and review of recent literature. Medicine (Baltimore). 1994;73(1):53-67. https://doi.org/10.1097/00005792-199401000-00005
  72. Miсano C, Garcia-Tsao G. Portal Hypertension. Gastroenterol Clin North Am. 2010;39(3):681-695. https://doi.org/10.1016/j.gtc.2010.08.015
  73. Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med (Maywood). 2011;236(5):557-566. https://doi.org/10.1258/ebm.2011.010375
  74. Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis: effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology. 1991;101(4):1060-1067. https://doi.org/10.1016/0016-5085(91)90734-3
  75. Gayowski T, Marino IR, Singh N, Doyle H, Wagener M, Fung JJ et al. Orthotopic liver transplantation in high-risk patients: Risk factors associated with mortality and infectious morbidity. Transplantation. 1998;65(4):499-504. https://doi.org/10.1097/00007890-199802270-00008
  76. Passarella M, Fallon MB, Kawut SM. Portopulmonary hypertension. Clin Liver Dis. 2006;10(3):653-663. https://doi.org/10.1016/j.cld.2006.08.023
  77. Zhang J, Ling Y, Tang L, Luo B, Chacko BK, Patel RP et al. Pentoxifylline attenuation of experimental hepatopulmonary syndrome. J Appl Physiol. 2007;102(3):949-955. https://doi.org/10.1152/japplphysiol.01048.2006
  78. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis. 2008;28(1):3-25. https://doi.org/10.1055/s-2008-1040318
  79. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. N Engl J Med. 1988;319(15):983-989.
  80. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103(7):1707-1715. https://doi.org/10.1111/j.1572-0241.2008.01861.x
  81. Brown MA, George CRP, Dunstan CR, Kalowski S, Corrigan AB. Prurigo nodularis and aluminium overload in maintenance haemodialysis. Lancet. 1992;340(8810):340-348. https://doi.org/10.1016/0140-6736(92)92458-R
  82. Ramsay M. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol. 2010;23(2):145-150. https://doi.org/10.1097/ACO.0b013e32833725c4
  83. Escorsell A, Bordas JM, del Arbol LR, Jaramillo JL, Planas R, Ba-ares R et al. Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. J Hepatol. 1998;29(5):779-788. https://doi.org/10.1016/S0168-8278(98)80259-6
  84. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut. 2001;49(4):577-583. https://doi.org/10.1136/gut.49.4.577
  85. Bennett RG, Mahan KJ, Gentry-Nielsen MJ, Tuma DJ. Relaxin receptor expression in hepatic stellate cells and in cirrhotic rat liver tissue. Ann NY Acad Sci. 2005;1041:185-189. https://doi.org/10.1196/annals.1282.027
  86. Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53(2):273-282. https://doi.org/10.1016/j.jhep.2010.03.013
  87. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337(7):473-479. https://doi.org/10.1056/NEJM199708143370707
  88. Lugo-Baruqui A, Mu-oz-Valle JF, Arévalo-Gallegos S, Armendáriz-Borunda J. Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. J Hepatol 2010;40(1):95-104. https://doi.org/10.1111/j.1872-034X.2009.00581.x
  89. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl. 2008;14(3):287-291. https://doi.org/10.1002/lt.21310
  90. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318.
  91. Stander S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol. 2001;44(3):471-478. https://doi.org/10.1067/mjd.2001.110059
  92. Suzuki Н, Stanley AJ. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. Quarterly J Med. 2001;94(6):293-300. https://doi.org/10.1093/qjmed/94.6.293
  93. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352-1359. https://doi.org/10.1053/j.gastro.2008.02.024
  94. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33(1):43-48. https://doi.org/10.1016/S0168-8278(00)80158-0
  95. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study. Hepatology. 2002;36(4 pt 1):941-948.
  96. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48(1 Suppl):68-92.
  97. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-849. https://doi.org/10.1002/bjs.1800600817
  98. Uribe M, Moran S. Dietetic manipulations in patients with hepatic encephalopathy. Rev Gastroenterol Mex. 1994;59(2 Suppl):74-78.